FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: Honda, Toyota China Sales Fall as Local EV Competition Intensifies

By

Honda Motor (TYO:7267) and Toyota Motor (TYO:7203) reported sharp sales declines in China in April as domestic competition intensified and weaker consumer demand weighed on the market, Nikkei reported Tuesday.

Honda's China sales fell 48% from a year earlier to 22,595 vehicles, with demand slowing for core models including the Accord. Sales at its joint venture with Guangzhou Automobile Group dropped 64%, while deliveries at its venture with Dongfeng Motor Group fell 31%, according to the report.

Honda said slower model updates hurt performance as Chinese brands and rivals accelerated new vehicle launches, the report said.

Toyota's April sales in China declined 25% to 106,500 vehicles. The company said higher gasoline prices weakened demand for combustion-engine cars, while some consumers delayed purchases ahead of May Day promotions, according to the report.

Sales at FAW Toyota fell 38%, while GAC Toyota posted a 10% decline. Deliveries for Toyota's Lexus marque dropped 29%. In contrast, Toyota's EV sales in China jumped 88% to 17,700 units. For the first four months of the year, Honda's China sales fell 28%, while Toyota recorded a 10% decline, the report said.

China's overall vehicle sales dropped 20% during the period, according to the China Association of Automobile Manufacturers, amid weak domestic demand and reduced tax incentives for electric and new-energy vehicles, according to the report.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Related Articles

Asia

Shenzhen LDROBOT Soars 103% in Hong Kong Trading Debut

Shenzhen LDROBOT's (HKG:1236) shares opened 102.9% above their initial public offering price in a stellar Hong Kong debut on Monday morning.The Chinese robotics company opened at HK$53.50 per share, well above the offer price of HK$26.36.

HKG:1236
Asia

Concord Healthcare to Issue HK$68 Million Convertible Bonds to CSPC Pharma Unit

Concord Healthcare (HKG:2453) agreed to issue HK$68 million of convertible bonds to a unit of CSPC Pharmaceutical (HKG:1093), according to a Monday Hong Kong bourse filing.The oncology healthcare service provider said Dragon Merit will subscribe to the 2% convertible bonds due in April 2027.The bonds are convertible into as many as 40 million Hong Kong-listed shares at an initial conversion price of HK$1.70 per share, representing a premium of about 14.1% to the stock's last closing price.Net proceeds of about HK$63.1 million will mainly be used to repay loans and supplement working capital.Concord Healthcare said the investment is expected to deepen cooperation with CSPC Pharmaceutical in the oncology healthcare sector.

HKG:1093HKG:2453
Asia

Alterity Therapeutics Says Peer-Reviewed Study Validates its Approach to Multiple System Atrophy; Shares Fall 9%

Alterity Therapeutics (ASX:ATH) said findings of a study published in the NeuroImage journal support quantitative susceptibility mapping as an objective imaging biomarker to facilitate the earlier diagnosis of multiple system atrophy (MSA), according to a Monday filing with the Australian bourse.Alterity is advancing its ATH434 lead candidate into a phase three program for multiple system atrophy, a neurodegenerative disease that leads to the failure of the autonomic nervous system and impaired movement.The company said it used quantitative susceptibility mapping in a phase two trial in which ATH434 helped improve diagnostic accuracy and provided "objective evidence of target engagement."The peer-reviewed publication validates the company's approach and "reinforces the role of [quantitative susceptibility mapping] as a biomarker for iron-modulating therapies in MSA," Alterity CEO David Stamler said.The company's shares fell 9% in recent Monday trade.

ASX:ATH